What is the 13F Pro Quality Score for HYPR?

13F Pro ranks Hyperfine, Inc. (HYPR) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View HYPR's current score at https://13fpro.ai/company/HYPR (free sign-up required for the full ranking).

Where does 13F Pro source HYPR data?

All Hyperfine, Inc. fundamentals and ownership data come directly from SEC EDGAR. Hyperfine, Inc. files with the SEC under CIK 1833769. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is HYPR in?

Hyperfine, Inc. (HYPR) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is HYPR research updated on 13F Pro?

HYPR's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Hyperfine, Inc.(HYPR)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1833769 HYPR stock profile & AI dashboard →

13F Pro Quality Score

31.7/100

Rank #2,445 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why HYPR Scores 32/100

exact factor attribution · 2026-09-11

HYPR's composite is driven by revenue growth and institutional flow, held back by scale and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+3.9 pts

69th pct

Institutional flow

+2.4 pts

97th pct

Earnings growth

+1.4 pts

77th pct

Earnings quality

-1.8 pts

32th pct

Shareholder dilution

-1.9 pts

13th pct

Capital efficiency

-4.3 pts

7th pct

Profitability

-5.9 pts

11th pct

Free cash flow

-6.0 pts

10th pct

Scale

-6.0 pts

10th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

HYPR Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Hyperfine, Inc. (HYPR), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores HYPR at 31.7/100 on a 32-signal composite quality model, placing it at rank #2,445 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Hyperfine, Inc. reports quarterly revenue of $3.9M, net income of $-9.3M, free cash flow of $-7.3M. Top institutional holders of HYPR by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, GEODE CAPITAL MANAGEMENT, based on the most recent SEC filings. HYPR trades on the Nasdaq exchange and files with the SEC under CIK 1833769. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate HYPR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Hyperfine, Inc. directly from SEC EDGAR. Hyperfine, Inc.'s 13F Pro composite quality score has ranged between 18 and 32 since 2022, currently 31.7 — a stable long-term trajectory across 16 quarterly and live scoring snapshots.

✦

Fun facts about Hyperfine, Inc.

Quirks, history, and lore behind HYPR — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. medical device company · small-cap · listed on Nasdaq · headquartered in Connecticut.
2
The Numbers
Revenue is in the low tens of millions annually — this is an early-stage company burning cash as it tries to crack a massive clinical market with novel hardware.
3
The History
Spun out of Yale University research, it went public via a SPAC merger around 2021, bringing lab-born imaging innovation into the commercial world.
4
The Secret
It is building a version of a decades-old diagnostic technology that has historically required a massive, shielded room — shrunk down to fit almost anywhere a patient might be.
5
The Lore
Its flagship device runs on standard electrical outlets — no special power supply, no million-dollar shielded suite — putting brain imaging in the ICU, the ER, even rural clinics.
6
The Giveaway
It makes the world's first FDA-cleared portable MRI system, designed to bring point-of-care brain scans to patients who can't be wheeled to a traditional scanner.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$3.9M

Net Income

Q2 2026

$-9.3M

Free Cash Flow

Q2 2026

$-7.3M

ROIC

Q2 2026

-67.8%

D/E Ratio

Q2 2026

0.36

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+5.2% YoY

$13.6MFY 2025

FY22 $6.8MFY23 $11.0MFY24 $12.9MFY25 $13.6M

Net Income

+12.6% YoY

$-35.6MFY 2025

FY22 $-44.2MFY23 $-44.2MFY24 $-40.7MFY25 $-35.6M

Operating Income

+14.2% YoY

$-37.1MFY 2025

FY22 $-73.9MFY23 $-48.1MFY24 $-43.2MFY25 $-37.1M

EPS (Diluted)

+23.2% YoY

$-0.43FY 2025

FY22 $-1.04FY23 $-0.62FY24 $-0.56FY25 $-0.43

Total Assets

-6.2% YoY

$55.3MFY 2025

FY22 $134.1MFY23 $94.2MFY24 $58.9MFY25 $55.3M

Total Debt

$0.00FY 2025

FY22 —FY23 —FY24 —FY25 $0.00

Op. Cash Flow

+27.9% YoY

$-27.9MFY 2025

FY22 $-72.3MFY23 $-41.8MFY24 $-38.8MFY25 $-27.9M

Free Cash Flow

+25.6% YoY

$-29.1MFY 2025

FY22 $-72.9MFY23 $-42.6MFY24 $-39.1MFY25 $-29.1M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$13.6M +5.2%	$12.9M +16.8%	$11.0M +61.9%	$6.8M +355.5%	$1.5M +408.8%	$294.0K
Net Income	$-35.6M +12.6%	$-40.7M +8.0%	$-44.2M +0.0%	$-44.2M +31.8%	$-64.9M -176.8%	$-23.4M
Operating Income	$-37.1M +14.2%	$-43.2M +10.2%	$-48.1M +34.9%	$-73.9M -13.9%	$-64.9M -176.1%	$-23.5M
EPS (Diluted)	$-0.43 +23.2%	$-0.56 +9.7%	$-0.62 +40.4%	$-1.04 +94.1%	$-17.57	—
Total Assets	$55.3M -6.2%	$58.9M -37.5%	$94.2M -29.7%	$134.1M -33.8%	$202.5M +183.1%	$71.5M
Total Debt	$0.00	—	—	—	—	—
Operating Cash Flow	$-27.9M +27.9%	$-38.8M +7.3%	$-41.8M +42.2%	$-72.3M -53.3%	$-47.2M -119.2%	$-21.5M
Free Cash Flow	$-29.1M +25.6%	$-39.1M +8.1%	$-42.6M +41.6%	$-72.9M -46.2%	$-49.9M -116.1%	$-23.1M

Get alerted when HYPR's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Hyperfine, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of HYPR

BlackRock, Inc.
$6.3M4,673,087 sh
VANGUARD CAPITAL MANAGEMENT LLC
$4.6M3,380,087 sh
GEODE CAPITAL MANAGEMENT, LLC
$2.6M1,960,811 sh
Fosun International Ltd
$2.4M1,742,020 sh
Catalio Capital Management, LP
$1.8M1,320,041 sh
STATE STREET CORP
$1.4M1,016,970 sh
RENAISSANCE TECHNOLOGIES LLC
$1.3M945,836 sh
Alphabet Inc.
$1.2M898,720 sh
NORTHERN TRUST CORP
$854.6K633,054 sh
VANGUARD FIDUCIARY TRUST CO
$765.6K567,109 sh

Fund	Value	Shares
BlackRock, Inc.	$6.3M	4,673,087
VANGUARD CAPITAL MANAGEMENT LLC	$4.6M	3,380,087
GEODE CAPITAL MANAGEMENT, LLC	$2.6M	1,960,811
Fosun International Ltd	$2.4M	1,742,020
Catalio Capital Management, LP	$1.8M	1,320,041
STATE STREET CORP	$1.4M	1,016,970
RENAISSANCE TECHNOLOGIES LLC	$1.3M	945,836
Alphabet Inc.	$1.2M	898,720
NORTHERN TRUST CORP	$854.6K	633,054
VANGUARD FIDUCIARY TRUST CO	$765.6K	567,109

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put HYPR on your watchlist

Track score changes the day Hyperfine, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is HYPR a good stock to buy?

13F Pro's AI-powered analysis of Hyperfine, Inc. (HYPR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for HYPR are available on the HYPR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. HYPR is classified as a small company.

Which hedge funds own HYPR?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling HYPR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Hyperfine, Inc.'s investment landscape.